Humansa and i-Cognitio Sciences Unveil the World's First AI-Powered Retinal Imaging for Alzheimer's Risk Detection
Revolutionizing Brain Health with CUHK Spin-off's Cutting-Edge Technology to Enable Early Detection and Prevention
HONG KONG SAR- Media OutReach Newswire – 29 May 2025 – Humansa, Asia's leading health and longevity center, is proud to announce the launch of its ground-breaking BrainSpark Program, a brain health program in collaboration with i-Cognitio Sciences, a spin-off company from the Chinese University of Hong Kong (CUHK) founded by Prof. Vincent Mok. This revolutionary program incorporates the world's first artificial intelligence (AI) model capable of detecting risk of Alzheimer's disease using fundus photographs alone, offering a non-invasive and accessible solution to address the growing global challenge of cognitive decline and dementia.
The Humansa management team and guests posed for a photo at the Humansa BrainSpark Brain Health Program event. (From left to right: Dr. Sanja Tomovska, member of the Humansa International Advisory Committee; Ms. Elaine Jiang, Founding Partner of Humansa; Professor Vincent Mok Chung-tong, Mok Hing Yiu Professor of Medicine of CUHK; Mr. Vincent Wong, Chief Commercial & Applied AI Officer of Humansa; Ms. Charmaine So, Wellness Coach at Humansa; Mr. Don So, CEO of Humansa.)
The Humansa BrainSpark Program is a timely response to the alarming statistics in developed Asia-Pacific regions, where the mean life expectancy has reached 85 years. Yet, 1 in 3 individuals aged 85 or above may suffer from dementia, a devastating disease that robs individuals of their independence and quality of life. Research shows that 45% of dementia cases can be prevented or delayed by optimizing modifiable risk factors, making early detection and personalized interventions critical.
ADVERTISEMENT
A Revolutionary Approach to Brain Health
The Humansa BrainSpark Program embodies a proactive approach to brain health by offering:
Comprehensive Brain Health Assessment: Powered by state-of-the-art AI retinal imaging technology (i-Cog Brain Health) led and developed by Prof. Vincent Mok's team, the program evaluates brain health and identifies early signals of Alzheimer's disease. The AI model, developed and validated using nearly 13,000 fundus photographs from 648 Alzheimer's patients and 3,240 cognitively normal subjects, demonstrated accuracies ranging from 80% to 92% among various datasets of multi-ethnicities and multi-countries. The study was led by CUHK in collaboration with Universities in Singapore (National University of Singapore, Duke-National University, Nanyang Technological University), China (Tsinghua University), US (Mayo Clinic) and UK (Queen's University Belfast). The findings were published in the prestigious Lancet Digital Health journal in 2022.
Tailor-Made Lifestyle Solutions: The Humansa BrainSpark Program offers tailor-made solutions that go beyond standard care, focusing on early detection and prevention of major chronic diseases, including Alzheimer's and dementia. By combining advanced AI technology with personalized care, Humansa provides lifestyle interventions, medical support, and preventive strategies tailored to each individual's unique risk profile. Additionally, Humansa's signature membership program offers a holistic anti-aging solution. This comprehensive package includes personalized recommendations on supplements, the frequency of restorative therapies, and other longevity strategies, empowering individuals to take proactive steps toward better brain health and overall well-being.
Professor Vincent Mok, Founding Director of i-Cognitio Sciences and Mok Hing Yiu Professor of Medicine of CUHK explains, 'The retina is an extension of the brain, and through non-invasive fundus photography, we can detect changes in the blood vessels and nerves of the retina that are associated with Alzheimer's disease. These changes can appear 10–15 years before symptoms develop, giving us a critical window for early intervention. This AI model can identify early microvascular changes associated with Alzheimer's disease that may not be detected even by conventional MRI, making it a powerful tool for identifying high-risk cases in both clinical and community settings.'
ADVERTISEMENT
Regarding the Humansa BrainSpark Program, Professor Mok adds, 'This program is an innovative initiative that combines cutting-edge AI technology with personalized care approach. It encourages individuals to take proactive steps to protect their brain health, enabling early preventive treatments and lifestyle changes that can slow cognitive decline and preserve quality of life.'
Aligning with Humansa's Methodology to Longevity
The newly launched Humansa BrainSpark Program is a cornerstone of Humansa's methodology to longevity and its signature Future Health Program, which emphasizes prevention, early detection, and personalized care. Cognitive function is a critical pillar of Humansa's longevity strategy, as maintaining brain health is essential for living a long, independent, and fulfilling life.
Don So, CEO of Humansa, shares, 'At Humansa, we believe that aging is not a passive process—it's a skill, a choice, and a science. Cognitive function is at the heart of our longevity strategy because it directly impacts an individual's ability to live independently and enjoy life to the fullest. The symptoms may show up decades later, but the seeds are often planted much earlier. The silent inflammation, the unchecked insulin resistance, and the daily choices—small and seemingly insignificant—that quietly shape your destiny. The Brain Health Program is a testament to our commitment to empowering individuals to live longer, healthier lives by providing them with the tools and knowledge to protect their brain health.'
A Call to Action
The Humansa BrainSpark Program combines cutting-edge technology with personalized care, offering individuals a proactive way to protect their brain health and live longer, healthier lives.
For more information or to schedule an assessment, please visit https://www.humansahealth.com.
Hashtag: #Humansa
The issuer is solely responsible for the content of this announcement.
About Humansa
Founded in 2020, Humansa is a pioneering health and wellness brand dedicated to empowering individuals to extend their healthspan and live life to the fullest. Headquartered in Hong Kong, Humansa operates over 40 centers and partners with a trusted network across the world. By integrating cutting-edge science with personalized care, Humansa is redefining the future of health and longevity.
Our offerings span proactive health assessments, evidence-based treatments, and continuous health optimization, setting a new standard in preventive and precision health.
Explore more at: www.humansahealth.com
About i-Cognitio Sciences
i-Cognitio Sciences is a spin-off medical technology company from CUHK, specializing in AI-driven ocular imaging technologies for brain health evaluation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
5 hours ago
- Arabian Post
Key Findings from the 'Hong Kong Vitiligo Patients and Caregivers Survey' Released for 'World Vitiligo Day'
Over 70% of Vitiligo Patients Desire Skin Repigmentation; New Topical Therapy Introduced in Hong Kong Shows Encouraging Results HONG KONG SAR – Media OutReach Newswire – 22 June 2025 – In observance of World Vitiligo Day (June 25), Hong Kong Vitiligo Support Group has released findings from its latest 'Hong Kong Vitiligo Patients and Caregivers Survey.' The study reveals critical gaps in treatment knowledge, with over 80% of respondents demonstrating limited understanding of available therapies and their efficacy. More than 70% of patients hoped therapy could partially or fully restore their original skin pigmentation, yet many reported disappointing outcomes with existing treatments, leading to loss of confidence and treatment discontinuation. ADVERTISEMENT (From left) Mr. Chan (pseudonym), a patient with vitiligo; Dr. Chan Yung, a specialist in dermatology; and Ms. Amy Wong, a registered social worker from the Hong Kong Vitiligo Support Group, urge individuals with vitiligo to seek professional medical consultation for personalized treatment plan promptly and to avoid unproven remedies Dr. Chan Yung, a specialist in dermatology, noted that with advancing insights into vitiligo pathogenesis, novel therapy has recently been introduced in Hong Kong. Clinical studies confirm its repigmentation potential, encouraging patients to consult specialists for personalized treatment plans. In Hong Kong, vitiligo affects approximately 1% of the population, with an estimated 70,000 individuals living with the condition. In May 2025, Hong Kong Vitiligo Support Group successfully surveyed 61 patients or their primary caregivers to identify key challenges in disease management. Key findings as follows: 1. Critical Knowledge Deficits in Treatment Understanding 80% lack understanding of treatment options 78% unfamiliar with medication efficacy 84% uncertain about which specialist to consult 2. Disparity Between Treatment Expectations and Outcomes 74% of respondents expressed a desire for full or partial skin repigmentation, yet among the 48 treated patients, none achieved complete repigmentation, and only 8% reported partial improvement 67% perceived treatments as completely ineffective 3. Treatment Discontinuation Due to Lost Confidence ADVERTISEMENT 43% are not receiving any active treatment at present Barriers included: high private healthcare costs and long public-sector wait times (95%), and perceived futility of therapy (75%) Vitiligo is classified as segmental (SV) or non-segmental (NSV), with 90% of cases being NSV—a subtype with higher progression risk and greater therapeutic difficulty. Traditional options (e.g., topical corticosteroids, topical calcineurin inhibitors, phototherapy) often yield variable results, with limitations such as: Corticosteroids: Risk of skin atrophy, telangiectasia; unsuitable for long-term use Phototherapy: Requires 3–6 months (or longer) of 2–3 weekly sessions, with potential sunburn and skin cancer risks Non-steroidal topicals: Often only slow progression rather than induce repigmentation Over 70% of Vitiligo Patients Seek Skin Repigmentation – New Topical Treatment Introduced in Hong Kong Offers Hope Dr. Chan Yung stated that targeted therapies like topical JAK inhibitors represent a breakthrough in vitiligo treatment. 'Topical JAK inhibitors are non-steroidal medications with demonstrated efficacy and safety profiles, making them a viable long-term treatment option for patients,' he explained. While the exact etiology of vitiligo remains unclear, current evidence suggests autoimmune-mediated attack on melanocytes plays a key pathogenic role, resulting in depigmented lesions. Non-steroidal Topical JAK inhibitors work by modulating the aberrant immune signaling responsible for melanocyte attack, enabling gradual repigmentation of affected areas. Ruxolitinib cream, the first FDA-approved non-steroidal topical JAK inhibitor for localized treatment of non-segmental vitiligo in patients aged 12 years and above, has recently become available in Hong Kong. Clinical trials show: Approximately 30% of patients achieved ≥75% improvement in Facial Vitiligo Area Scoring Index (F-VASI) after 24 weeks of treatment; 50% of patients showed ≥50% improvement; Extension to 52 weeks of treatment resulted in >50% of patients attaining ≥75% improvement7 Ms. Amy Wong, a Registered Social Worker at Hong Kong Vitiligo Support Group noted that many vitiligo patients and caregivers seeking assistance express confusion about treatment options and medication efficacy. 'Many patients spend over a year just obtaining a definitive diagnosis,' she explained. 'In their search for solutions, patients often invest substantial resources in various cosmetic packages and alternative therapies, only to experience significant discrepancies between desired and actual outcomes. This frequently leads to disillusionment, loss of hope for effective treatment, and even emotional distress.' 'However,' Ms. Wong emphasized, 'with medical advancements, vitiligo is no longer considered untreatable. Repigmentation is now achievable, and we strongly encourage patients to seek professional medical consultation at the earliest opportunity.' Conclusion and Recommendations The survey reveals significant gaps in patients' understanding of vitiligo treatments and their mechanisms, leaving many uncertain about where to begin treatment. Over 80% of respondents expressed desire for patient support in medication access and resource referrals. Accordingly, Dr. Chan Yung and Ms. Amy Wong, propose the following recommendations: 1. Public Education Seminars Conduct lectures and workshops to help patients and caregivers understand that vitiligo requires long-term management, with visible results often taking extended periods to manifest. These initiatives should also educate participants about various treatment modalities, particularly newly available options like non-steroidal topical JAK inhibitors, enabling informed discussions with healthcare providers about appropriate treatment plans. 2. Medication Support and Resource Referral Services Given that vitiligo necessitates prolonged treatment, and considering that many patients find private care cost-prohibitive while public service wait times are excessively long, we recommend establishing medication support and resource referral services to facilitate timely access to proper treatment. Hong Kong Vitiligo Support Group is currently implementing a 'Vitiligo Patient Support Program,' offering free psychological counseling, medication assistance, and resource referral services. Interested individuals may contact Hong Kong Vitiligo Support Group for details. Case Study Mr. Chan (pseudonym), 58, first developed symptoms thirty years ago with a small depigmented spot on his neck that subsequently spread to his neck, waist, wrists, and thighs. At diagnosis, his physician prescribed topical corticosteroids but stated vitiligo was essentially 'incurable.' Mr. Chan subsequently pursued numerous alternative treatments including UV light therapy, traditional Chinese medicine, electroacupuncture, topical shampoo applications, and cosmetic packages – exhausting savings and liquidating his stocks – all without achieving satisfactory repigmentation. After years of unsuccessful treatment attempts, he discontinued treatment until being referred to the Hong Kong Vitiligo Support Group. Through their seminars and 'Vitiligo Patient Support Program', he learned about modern treatment advances and, with medication assistance, has begun new therapy with renewed hope for repigmentation. 'My greatest wish is to wear crew-neck shirts again,' Mr. Chan shared. 'Since developing vitiligo, I've only worn high-collared shirts to conceal neck patches and haven't gone swimming in thirty years.' He looks forward to regaining sartorial freedom following successful repigmentation. Hashtag: #Vitiligo #WorldVitiligoDay #TopicalJAKinhibitors #Non-steroidalTopicalJAKinhibitors #Ruxolitinibcream #SkinRepigmentation # #Dermatology #Skincare#HongKongVitiligoSupportGroup The issuer is solely responsible for the content of this announcement. About Hong Kong Vitiligo Support Group Initiated by social enterprise Hong Kong Health Care Alliance, Hong Kong Vitiligo Support Group is a non-profit patient organization dedicated to individuals affected by vitiligo and their caregivers. Our mission is to enhance societal understanding of vitiligo through comprehensive disease education and support services, empowering patients to better understand and confront their condition while fostering public awareness. We strive to ensure no patient faces this journey alone.
Arabian Post
4 days ago
- Arabian Post
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. ISTANBUL, TURKEY – Media OutReach Newswire – 18 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. Key findings from the report include: Rapid expansion : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. High scholarly impact : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. Interdisciplinary breadth : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. Global collaboration hubs : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. Emerging research foci : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. Societal resonance: 11.1% of research outputs were mentioned on social media and 2.9% cited in policy documents, reflecting growing public and policymaker interest. Bridging a global integration gap ADVERTISEMENT Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
Arabian Post
5 days ago
- Arabian Post
Hong Kong Baptist University and Elsevier Report Charts Global Growth of Chinese Medicine Research, Calls for Standardised Frameworks for Broader Integration
HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. ISTANBUL, TURKEY – Media OutReach Newswire – 17 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. Key findings from the report include: Rapid expansion : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. High scholarly impact : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. Interdisciplinary breadth : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. Global collaboration hubs : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. Emerging research foci : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. Societal resonance: 11.1% of research outputs were mentioned on social media and 2.9% cited in policy documents, reflecting growing public and policymaker interest. Bridging a global integration gap ADVERTISEMENT Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
